These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36590455)

  • 1. The glucocerebrosidase mutations and uric acid levels in Parkinson's disease: A 3-years investigation of a potential biomarker".
    Mozafar M; Kazemian S; Hoseini E; Mohammadi M; Alimoghadam R; Shafie M; Mayeli M;
    Clin Park Relat Disord; 2023; 8():100177. PubMed ID: 36590455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocerebrosidase Mutations and Motor Reserve in Parkinson's Disease.
    Chung SJ; Lee PH; Sohn YH; Kim YJ
    J Parkinsons Dis; 2021; 11(4):1715-1724. PubMed ID: 34459414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor subtypes and clinical characteristics in sporadic and genetic Parkinson's disease groups: analysis of the PPMI cohort.
    Jeong EH; Lee JY; Han SK; Song YS
    Front Neurol; 2023; 14():1276251. PubMed ID: 37954645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study.
    Koros C; Simitsi AM; Papagiannakis N; Bougea A; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Parkinsonism Relat Disord; 2021 Mar; 84():1-4. PubMed ID: 33508700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of prodromal parkinsonian features in a cohort of
    Avenali M; Toffoli M; Mullin S; McNeil A; Hughes DA; Mehta A; Blandini F; Schapira AHV
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1091-1097. PubMed ID: 31221723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study.
    Grisanti S; Fraternali A; Cavallieri F; Fioravanti V; Casali M; Toschi G; Ferri L; Sabadini R; Zedde M; Salomone G; Napoli M; Pascarella R; Ferrari V; Scarano M; Biagini G; Scaglioni A; Moro E; Versari A; Valzania F
    Brain Behav; 2023 Jul; 13(7):e3060. PubMed ID: 37264751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
    Pagano G; Boess FG; Taylor KI; Ricci B; Mollenhauer B; Poewe W; Boulay A; Anzures-Cabrera J; Vogt A; Marchesi M; Post A; Nikolcheva T; Kinney GG; Zago WM; Ness DK; Svoboda H; Britschgi M; Ostrowitzki S; Simuni T; Marek K; Koller M; Sevigny J; Doody R; Fontoura P; Umbricht D; Bonni A; ;
    Front Neurol; 2021; 12():705407. PubMed ID: 34659081
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
    Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
    Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
    Davis MY; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Chen-Plotkin A; Van Deerlin VM; Quinn JF; Chung KA; Peterson-Hiller AL; Rosenthal LS; Dawson TM; Albert MS; Goldman JG; Stebbins GT; Bernard B; Wszolek ZK; Ross OA; Dickson DW; Eidelberg D; Mattis PJ; Niethammer M; Yearout D; Hu SC; Cholerton BA; Smith M; Mata IF; Montine TJ; Edwards KL; Zabetian CP
    JAMA Neurol; 2016 Oct; 73(10):1217-1224. PubMed ID: 27571329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
    Alcalay RN; Wolf P; Chiang MSR; Helesicova K; Zhang XK; Merchant K; Hutten SJ; Scherzer C; Caspell-Garcia C; Blauwendraat C; Foroud T; Nudelman K; Gan-Or Z; Simuni T; Chahine LM; Levy O; Zheng D; Li G; Sardi SP;
    Ann Clin Transl Neurol; 2020 Oct; 7(10):1816-1830. PubMed ID: 32888397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Monitoring of Parkinson's Disease in Different Ethnic Cohorts: The DodoNA and LONG-PD Study.
    Markopoulou K; Aasly J; Chung SJ; Dardiotis E; Wirdefeldt K; Premkumar AP; Schoneburg B; Kartha N; Wilk G; Wei J; Simon KC; Tideman S; Epshteyn A; Hadsell B; Garduno L; Pham A; Frigerio R; Maraganore D
    Front Neurol; 2020; 11():548. PubMed ID: 32733352
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of cognitive impairment in newly diagnosed Parkinson's disease with normal cognition at baseline: A 5-year cohort study.
    Chen J; Zhao D; Wang Q; Chen J; Bai C; Li Y; Guo X; Chen B; Zhang L; Yuan J
    Front Aging Neurosci; 2023; 15():1142558. PubMed ID: 36926634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
    Skorvanek M; Martinez-Martin P; Kovacs N; Rodriguez-Violante M; Corvol JC; Taba P; Seppi K; Levin O; Schrag A; Foltynie T; Alvarez-Sanchez M; Arakaki T; Aschermann Z; Aviles-Olmos I; Benchetrit E; Benoit C; Bergareche-Yarza A; Cervantes-Arriaga A; Chade A; Cormier F; Datieva V; Gallagher DA; Garretto N; Gdovinova Z; Gershanik O; Grofik M; Han V; Huang J; Kadastik-Eerme L; Kurtis MM; Mangone G; Martinez-Castrillo JC; Mendoza-Rodriguez A; Minar M; Moore HP; Muldmaa M; Mueller C; Pinter B; Poewe W; Rallmann K; Reiter E; Rodriguez-Blazquez C; Singer C; Tilley BC; Valkovic P; Goetz CG; Stebbins GT
    Mov Disord Clin Pract; 2017; 4(4):536-544. PubMed ID: 30363418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.